Transcriptional Activation of the Suppressor of Cytokine Signaling-3 (SOCS-3) Gene via STAT3 Is Increased in F9 REX1 (ZFP-42) Knockout Teratocarcinoma Stem Cells Relative to Wild-type Cells

Journal of Molecular Biology

Volumn 377, Issue 1, 2008, Pages 28-46

  Xu, Juliana ^a   Sylvester, Renia ^a   Tighe, Ann P ^a   Chen, Siming ^a   Gudas, Lorraine J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cancer; dibutyryl cyclic AMP; retinoic acid; stem cells; zinc finger transcription factor

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; JANUS KINASE 2; MERCAPTOETHANOL; PARATHYROID HORMONE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; THEOPHYLLINE;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA BINDING; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TERATOCARCINOMA; TRANSCRIPTION INITIATION; TRANSIENT TRANSFECTION; WILD TYPE;

EID: 39649125414     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.12.038     Document Type: Article

References (104)

1. Gudas L.J. Molecular mechanisms of retinoid action. Am. J. Respir. Cell Mol. Biol. 2 (1990) 319-320
2. Gudas L.J. Retinoids and vertebrate development. J. Biol. Chem. 269 (1994) 15399-15402
3. Means A.L., and Gudas L.J. The roles of retinoids in vertebrate development. Annu. Rev. Biochem. 64 (1995) 210-233
4. Mongan, N. P. & Gudas, L. J. Diverse actions of retinoid receptors in cancer prevention and treatment. Differentiation. 74, 853-870.
5. Mark M., Ghyselinck N.B., and Chambon P. Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 451-480
6. Hosler B.A., LaRosa G.J., Grippo J.F., and Gudas L.J. Expression of REX-1, a gene containing zinc finger motifs, is rapidly reduced by retinoic acid in F9 teratocarcinoma cells. Mol. Cell Biol. 9 (1989) 5623-5629
7. Stevens L.C. The origin and development of testicular, ovarian and embryo-derived teratocarcinomas. Teratocarcinoma Stem Cells vol. 10 (1983), Cold Spring Harbor Laboratory Press, New York
8. Kaczynski J., Cook T., and Urrutia R. Sp1- and Kruppel-like transcription factors. Genome Biol. 4 (2003) 206
9. Mongan N.P., Martin K.M., and Gudas L.J. The putative human stem cell marker, Rex-1 (Zfp42): structural classification and expression in normal human epithelial and carcinoma cell cultures. Mol. Carcinog. 45 (2006) 887-900
10. Rogers M.B., Hosler B.A., and Gudas L.J. Specific expression of a retinoic acid-regulated, zinc-finger gene, Rex-1, in preimplantation embryos, trophoblast and spermatocytes. Development 113 (1991) 815-824
11. Shi W., Wang H., Pan G., Geng Y., Guo Y., and Pei D. Regulation of the pluripotency marker Rex-1 by Nanog and Sox2. J. Biol. Chem. 281 (2006) 23319-23325
12. Scherer C.A., Chen J., Nachabeh A., Hopkins N., and Ruley H.E. Transcriptional specificity of the pluripotent embryonic stem cell. Cell Growth Differ. 7 (1996) 1393-1401
13. Ramalho-Santos M., Yoon S., Matsuzaki Y., Mulligan R.C., and Melton D.A. "Stemness": transcriptional profiling of embryonic and adult stem cells. Science 298 (2002) 597-600
14. Goolsby J., Marty M.C., Heletz D., Chiappelli J., Tashko G., Yarnell D., et al. Hematopoietic progenitors express neural genes. Proc. Natl Acad. Sci. USA 100 (2003) 14926-14931
15. Sato N., Meijer L., Skaltsounis L., Greengard P., and Brivanlou A.H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 10 (2004) 55-63
16. Verfaillie C.M. Adult stem cells: assessing the case for pluripotency. Trends Cell Biol. 12 (2002) 502-508
17. Jiang Y., Vaessen B., Lenvik T., Blackstad M., Reyes M., and Verfaillie C.M. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp. Hematol. 30 (2002) 896-904
18. Jiang Y., Henderson D., Blackstad M., Chen A., Miller R.F., and Verfaillie C.M. Neuroectodermal differentiation from mouse multipotent adult progenitor cells. Proc. Natl Acad. Sci. USA 1 (2003) 11854-11860
19. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-Gonzalez X.R., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418 (2002) 41-49
20. Kucia M., Reca R., Campbell F.R., Zuba-Surma E., Majka M., Ratajczak J., and Ratajczak M.Z. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia 20 (2006) 857-869
21. Raman J.D., Mongan N.P., Liu L., Tickoo S.K., Nanus D.M., Scherr D.S., and Gudas L.J. Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma. Carcinogenesis 27 (2006) 499-507
22. Thompson J.R., and Gudas L.J. Retinoic acid induces parietal endoderm but not primitive endoderm and visceral endoderm differentiation in F9 teratocarcinoma stem cells with a targeted deletion of the Rex-1 (Zfp-42) gene. Mol. Cell. Endocrinol. 195 (2002) 119-133
23. Zhong Z., Wen Z., and Darnell Jr. J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264 (1994) 95-98
24. Horvath C.M. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem. Sci. 25 (2000) 496-502
25. Levy D.E., and Lee C.K. What does Stat3 do?. J. Clin. Invest. 109 (2002) 1143-1148
26. Levy D.E., and Darnell Jr. J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3 (2002) 651-662
27. Dauer D.J., Ferraro B., Song L., Yu B., Mora L., Buettner R., et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 24 (2005) 3397-3408
28. Calo V., Migliavacca M., Bazan V., Macaluso M., Buscemi M., Gebbia N., and Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. 197 (2003) 157-168
29. Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 109 (2002) 1139-1142
30. Chan K.S., Sano S., Kiguchi K., Anders J., Komazawa N., Takeda J., and DiGiovanni J. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J. Clin. Invest. 114 (2004) 720-728
31. Dong S., Chen S.J., and Tweardy D.J. Cross-talk between retinoic acid and STAT3 signaling pathways in acute promyelocytic leukemia. Leuk. Lymphoma 44 (2003) 2023-2029
32. Quadros M.R., Peruzzi F., Kari C., and Rodeck U. Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Cancer Res. 64 (2004) 3934-3939
33. Leeman R.J., Lui V.W., and Grandis J.R. STAT3 as a therapeutic target in head and neck cancer. Expert Opin. Biol. Ther. 6 (2006) 231-241
34. Xi S., Gooding W.E., and Grandis J.R. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 24 (2005) 970-979
35. Xu Q., Briggs J., Park S., Niu G., Kortylewski M., Zhang S., et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24 (2005) 5552-5560
36. Takeda K., Noguchi K., Shi W., Tanaka T., Matsumoto M., Yoshida N., et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl Acad. Sci. USA 94 (1997) 3801-3804
37. Hilton D.J. Negative regulators of cytokine signal transduction. Cell Mol. Life Sci. 55 (1999) 1568-1577
38. Krebs D.L., and Hilton D.J. SOCS: physiological suppressors of cytokine signaling. J. Cell Sci. 113 (2000) 2813-2819
39. Auernhammer C.J., and Melmed S. The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. J. Clin. Invest. 108 (2001) 1735-1740
40. Nicholson S.E., De Souza D., Fabri L.J., Corbin J., Willson T.A., Zhang J.G., et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl Acad. Sci. USA 97 (2000) 6493-6498
41. Bousquet C., Susini C., and Melmed S. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J. Clin. Invest. 104 (1999) 1277-1285
42. Auernhammer C.J., Bousquet C., and Melmed S. Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc. Natl Acad. Sci. USA 96 (1999) 6964-6969
43. O'Shea J.J., Gadina M., and Schreiber R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 (2002) S121-S131 (Suppl.)
44. Forrai A., Boyle K., Hart A.H., Hartley L., Rakar S., and Willson T.A. Absence of suppressor of cytokine signalling 3 reduces self-renewal and promotes differentiation in murine embryonic stem cells. Stem Cells 24 (2006) 604-614
45. Spangenburg E.E. SOCS-3 induces myoblast differentiation. J. Biol. Chem. 280 (2005) 10749-10758
46. Raccurt M., Tam S.P., Lau P., Mertani H.C., Lambert A., Garcia-Caballero T., et al. Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br. J. Cancer 89 (2003) 524-532
47. Brender C., Nielsen M., Kaltoft K., Mikkelsen G., Zhang Q., Wasik M., et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 97 (2001) 1056-1062
48. Weber A., Hengge U.R., Bardenheuer W., Tischoff I., Sommerer F., Markwarth A., et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24 (2005) 6699-6708
49. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitagawa T., et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24 (2005) 6406-6417
50. Ueki K., Kondo T., and Kahn C.R. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell. Biol. 24 (2004) 5434-5446
51. Steppan C.M., Wang J., Whiteman E.L., Birnbaum M.J., and Lazar M.A. Activation of SOCS-3 by resistin. Mol. Cell. Biol. 25 (2005) 1569-1575
52. Takahashi Y., Carpino N., Cross J.C., Torres M., Parganas E., and Ihle J.N. SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. EMBO J. 22 (2003) 372-384
53. Roberts A.W., Robb L., Rakar S., Hartley L., Cluse L., Nicola N.A., et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc. Natl Acad. Sci. USA 98 (2001) 9324-9329
54. Wang S.Y., LaRosa G.J., and Gudas L.J. Molecular cloning of gene sequences transcriptionally regulated by retinoic acid and dibutyryl cyclic AMP in cultured mouse teratocarcinoma cells. Dev. Biol. 107 (1985) 75-86
55. Wang S.Y., and Gudas L.J. Isolation of cDNA clones specific for collagen IV and laminin from mouse teratocarcinoma cells. Proc. Natl Acad. Sci. USA 80 (1983) 5880-5884
56. Strickland S., Smith K.K., and Marotti K.R. Hormonal induction of differentiation in teratocarcinoma stem cells: generation of parietal endoderm by retinoic acid and dibutyryl cAMP. Cell 21 (1980) 347-355
57. LaRosa G.J., and Gudas L.J. Early retinoic acid-induced F9 teratocarcinoma stem cell gene ERA-1: alternate splicing creates transcripts for a homeobox-containing protein and one lacking the homeobox. Mol. Cell. Biol. 8 (1988) 3906-3917
58. Hogan B.L.M., Taylor A., and Adamson E. Cell interactions modulate embryonal carcinoma cell differentiation into parietal or visceral endoderm. Nature 291 (1981) 235-237
59. Nomiyama H., Fromental C., Xiao J.H., and Chambon P. Cell-specific activity of the constituent elements of the simian virus 40 enhancer. Proc. Natl Acad. Sci. USA 84 (1987) 7881-7885
60. Minami M., Inoue M., Wei S., Takeda K., Matsumoto M., Kishimoto T., and Akira S. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc. Natl Acad. Sci. USA 93 (1996) 3963-3966
61. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., and Darnell Jr. J.E. Stat3 as an oncogene. Cell 98 (1999) 295-303
62. Li L., and Shaw P.E. Elevated activity of STAT3C due to higher DNA binding affinity of phosphotyrosine dimer rather than covalent dimer formation. J. Biol. Chem. 281 (2006) 33172-33181
63. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 67 (1998) 227-264
64. O'Shea J.J. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet?. Immunity 7 (1997) 1-11
65. Cooper D.M. Regulation and organization of adenylyl cyclases and cAMP. Biochem. J. 375 (2003) 517-529
66. Steinberg R.A., O'Farrell P.H., Friedrich U., and Coffino P. Mutations causing charge alterations in regulatory subunits of the cAMP-dependent protein kinase of cultured S49 lymphoma cells. Cell 10 (1977) 381-391
67. Correll L.A., Woodford T.A., Corbin J.D., Mellon P.L., and McKnight G.S. Functional characterization of cAMP-binding mutations in type I protein kinase. J. Biol. Chem. 264 (1989) 16672-16678
68. Kopperud R., Krakstad C., Selheim F., and Doskeland S.O. cAMP effector mechanisms. Novel twists for an 'old' signaling system. FEBS Lett. 546 (2003) 121-126
69. Akira S., Nishio Y., Inoue M., Wang X.J., Wei S., Matsusaka T., et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77 (1994) 63-71
70. Aringer M., Cheng A., Nelson J.W., Chen M., Sudarshan C., Zhou Y.J., and O'Shea J.J. Janus kinases and their role in growth and disease. Life Sci. 64 (1999) 2173-2186
71. Ihle J.N. STATs: signal transducers and activators of transcription. Cell 84 (1996) 331-334
72. Darnell Jr. J.E. STATs and gene regulation. Science 277 (1997) 1630-1635
73. Zong C.S., Chan J., Levy D.E., Horvath C., Sadowski H.B., and Wang L.H. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J. Biol. Chem. 275 (2000) 15099-15105
74. Liu A.M., Lo R.K., Wong C.S., Morris C., Wise H., and Wong Y.H. Activation of STAT3 by G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase. J. Biol. Chem. 281 (2006) 35812-35825
75. Simon A.R., Rai U., Fanburg B.L., and Cochran B.H. Activation of the JAK-STAT pathway by reactive oxygen species. Am. J. Physiol. 275 (1998) C1640-C1652
76. Wang Y.Z., Wharton W., Garcia R., Kraker A., Jove R., and Pledger W.J. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity. Oncogene 19 (2000) 2075-2085
77. Bowman T., Broome M.A., Sinibaldi D., Wharton W., Pledger W.J., and Sedivy J.M. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl Acad. Sci. USA 98 (2001) 7319-7324
78. Garcia R., and Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biomed. Sci. 5 (1998) 79-85
79. Aitken R.J., Buckingham D.W., and Irvine D.S. The extragenomic action of progesterone on human spermatozoa: evidence for a ubiquitous response that is rapidly down-regulated. Endocrinology 137 (1996) 3999-4009
80. Chiarugi P. Reactive oxygen species as mediators of cell adhesion. Ital. J. Biochem. 52 (2003) 28-32
81. Starr R., and Hilton D.J. SOCS: suppressors of cytokine signalling. Int. J. Biochem. Cell Biol. 30 (1998) 1081-1085
82. Nicholson S.E., Willson T.A., Farley A., Starr R., Zhang J.G., Baca M., et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 18 (1999) 375-385
83. Bousquet C., Chesnokova V., Kariagina A., Ferrand A., and Melmed S. cAMP neuropeptide agonists induce pituitary suppressor of cytokine signaling-3: novel negative feedback mechanism for corticotroph cytokine action. Mol. Endocrinol. 15 (2001) 1880-1890
84. Taneja R., Rochette-Egly C., Plassat J.L., Penna L., Gaub M.P., and Chambon P. Phosphorylation of activation functions AF-1 and AF-2 of RAR alpha and RAR gamma is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment. EMBO J. 16 (1997) 6452-6465
85. Huggenvik J.I., Collard M.W., Kim Y.W., and Sharma R.P. Modification of the retinoic acid signaling pathway by the catalytic subunit of protein kinase-A. Mol. Endocrinol. 7 (1993) 543-550
86. Ruff-Jamison S., Chen K., and Cohen S. Epidermal growth factor induces the tyrosine phosphorylation and nuclear translocation of Stat 5 in mouse liver. Proc. Natl Acad. Sci. USA 92 (1995) 4215-4218
87. Dong S., and Tweardy D.J. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood 99 (2002) 2637-2646
88. Grandis J.R., Drenning S.D., Chakraborty A., Zhou M.Y., Zeng Q., Pitt A.S., and Tweardy D.J. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J. Clin. Invest. 102 (1998) 1385-1392
89. Olayioye M.A., Beuvink I., Horsch K., Daly J.M., and Hynes N.E. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J. Biol. Chem. 274 (1999) 17209-17218
90. Niwa H., Burdon T., Chambers I., and Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 12 (1998) 2048-2060
91. Matsuda T., Nakamura T., Nakao K., Arai T., Katsuki M., Heike T., and Yokota T. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J. 18 (1999) 4261-4269
92. Lehtonen E., Laasonen A., and Tienari J. Teratocarcinoma stem cells as a model for differentiation in the mouse embryo. Int. J. Dev. Biol. 33 (1989) 105-115
93. Lang R., Pauleau A.L., Parganas E., Takahashi Y., Mages J., Ihle J.N., et al. SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 4 (2003) 546-550
94. Pelletier S., Duhamel F., Coulombe P., Popoff M.R., and Meloche S. Rho family GTPases are required for activation of Jak/STAT signaling by G protein-coupled receptors. Mol. Cell. Biol. 23 (2003) 1316-1333
95. Gudas L.J., Sporn M.B., and Roberts A.B. Cellular biology and biochemistry of the retinoids. In: Sporn M.B., Roberts A.B., and Goodman D.S. (Eds). The Retinoids: Biology, Chemistry, and Medicine. 2nd edit. (1994), Raven Press, New York
96. Yoneda T., Niewolna M., Lowe C., Izbicka E., and Mundy G.R. Hormonal regulation of pp60c-src expression during osteoclast formation in vitro. Mol. Endocrinol. 7 (1993) 1313-1318
97. Goldshmit Y., Walters C.E., Scott H.J., Greenhalgh C.J., and Turnley A.M. SOCS2 induces neurite outgrowth by regulation of epidermal growth factor receptor activation. J. Biol. Chem. 279 (2004) 16349-16355
98. Alchanati I., Nallar S.C., Sun P., Gao L., Hu J., Stein A., et al. A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 25 (2006) 7138-7147
99. Kalakonda S., Nallar S.C., Lindner D.J., Hu J., Reddy S.P., and Kalvakolanu D.V. Tumor-suppressive activity of the cell death activator GRIM-19 on a constitutively active signal transducer and activator of transcription 3. Cancer Res. 67 (2007) 6212-6220
100. Lufei C., Ma J., Huang G., Zhang T., Novotny-Diermayr V., Ong C.T., and Cao X. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J. 22 (2003) 1325-1335
101. Zhang J., Yang J., Roy S.K., Tininini S., Hu J., Bromberg J.F., et al. The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc. Natl Acad. Sci. USA 100 (2003) 9342-9347
102. Vasios G.W., Gold J.D., Petkovich M., Chambon P., and Gudas L.J. A retinoic acid-responsive element is present in the 5′ flanking region of the laminin B1 gene. Proc. Natl Acad. Sci. USA 86 (1989) 9099-9103
103. Ben-Shushan E., Thompson J.R., Gudas L.J., and Bergman Y. Rex-1, a gene encoding a transcription factor expressed in the early embryo, is regulated via Oct-3/4 and Oct-6 binding to an octamer site and a novel protein, Rox-1, binding to an adjacent site. Mol. Cell. Biol. 18 (1998) 1866-1878
104. Boylan J.F., Lohnes D., Taneja R., Chambon P., and Gudas L.J. Loss of retinoic acid receptor gamma function in F9 cells by gene disruption results in aberrant Hoxa-1 expression and differentiation upon retinoic acid treatment. Proc. Natl Acad. Sci. USA 90 (1993) 9601-9605